Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).

Pierre FrangeF VeberM BurgardS BlancheV Avettand-Fenoel

Published in: HIV medicine (2023)

Because of its high genetic barrier to resistance, BIC/FTC/TAF could be especially useful in the paediatric population, in which the risk of poor treatment adherence and VF is high.

Keyphrases

intensive care unit
emergency department
genome wide
gene expression
type diabetes
antiretroviral therapy
combination therapy
adipose tissue